Effects of isolated isoflavonoids on lipids, lipoproteins, insulin sensitivity, and ghrelin in postmenopausal women

What Was Tested

This randomized controlled trial paper looks at Ghrelin.

The low cardiovascular risk in Asian women has been thought to result from high isoflavonoid intake.

The concentrations of total cholesterol, high- and low-density lipoprotein cholesterol, triglycerides, apolipoproteins B and A1, and lipoprotein (a) were not affected by isoflavonoids.

Who Took Part

According to the abstract, 56 women were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, women only.

Isoflavonoid or placebo tablets were given for 3 months, and the treatment regimens crossed over after a 2-month washout period.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.

As a double-blind Ghrelin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Ghrelin could be set against what happens without it.

In the crossover set-up each of the women took both Ghrelin and the comparison in turn, acting as their own control.

The timeline in the abstract includes 3 months.

What Was Measured

PubMed files the paper under topics including Ghrelin, Glucose Tolerance Test, Insulin Resistance, Isoflavones, Lipids, Lipoproteins and Lipoproteins, LDL.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin in 56 women over 3 months.

The publication is from 2004 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Ghrelin compound page, all human trials.